New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 22, 2013
20:25 EDTMOLX, MOLX, CMC, CMC, UNF, UNF, PB, PB, ROL, ROL, LCC, LCC, OC, OC, TUP, TUP, NDAQ, NDAQ, OCR, OCR, MDCO, MDCONotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Molex (MOLX), consensus 37c; Omnicare (OCR), consensus 90c; Nasdaq OMX (NDAQ), consensus 62c; Tupperware (TUP), consensus $1.03; Owens Corning (OC), consensus 65c; US Airways (LCC), consensus $1.12; Rollins (ROL), consensus 24c; Prosperity Bancshares (PB), consensus 90c; UniFirst (UNF), consensus $1.40; Commercial Metals (CMC), consensus 17c; The Medicines Company (MDCO), consensus 21c.
News For MOLX;OCR;NDAQ;TUP;OC;LCC;ROL;PB;UNF;CMC;MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:41 EDTMDCOThe Medicines Co. upgraded at Credit Suisse
Subscribe for More Information
06:06 EDTMDCOThe Medicines Co. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 19, 2014
07:47 EDTNDAQKeefe Bruyette to hold a conference
Securities Brokerage & Market Structure Conference is being held in New York on November 19 with webcasted company presentations to begin at 7:45 am. Webcast Link
November 18, 2014
11:36 EDTTUPTupperware Brands sees local currency sales in 2015 up 4%-6%
Comments from slide presentation.
11:15 EDTTUPTupperware Brands backs FY14 EPS view $5.21-$5.26, consensus $5.25
Subscribe for More Information
11:13 EDTTUPTupperware Brands backs Q4 earnings view $1.55-$1.60, consensus $1.57
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information
November 12, 2014
08:19 EDTUNFJPMorgan to hold a conference
Subscribe for More Information
08:13 EDTNDAQBoston Biotech to hold a conference
Subscribe for More Information
November 11, 2014
10:20 EDTOCRHigh option volume stocks
High option volume stocks: RLGY TWC LITB SPM ACRX JWN OCR CALL CST ERIC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use